Teplizumab, a new drug, could delay the need for insulin for patients with type 1 diabetes by up to 3 years.
Călin Nicolescu
Health
Foto Pixabay
Always see our news on Google
Teplizumab, a drug already approved in the US, is being tested in the UK to slow the progression of type 1 diabetes by training the immune system to protect pancreatic cells. Hannah Robinson, the first British adult to receive the treatment, hopes it will delay the need for insulin. Experts believe the treatment represents a major change in diabetes management, with the potential to alter the immune process and help high-risk people avoid insulin therapy.
Sources
Un medicament "revoluţionar" ar putea încetini evoluţia diabetului de tip 1. Poate întârzia nevoia de insulină cu 3 ani
Devon mother treated with game-changing diabetes drug
Mother of two becomes the first UK patient to receive ‘groundbreaking’ new diabetes drug
Un medicament „revoluționar”, o nouă speranță pentru diabetul de tip 1. Ce așteptări au medicii
Latest News
10:32
Tensions at the protest in front of ANSVSA, after farmers tried to enter the institution, and the gendarmes used tear gas.
10:31
AUR accuses the PSD-PNL-USR-UDMR coalition of undermining democracy
10:22
The schedule of Romanian teams in the Conference League qualifiers! When do the red and blue play, "U" Cluj and CFR Cluj / Where can the matches be watched
10:13
Devastating fires in Greece: Three firefighters died during the wildfires in Crete and Peloponnese
10:10
A drone struck a gas tanker owned by an American company in the port of Damietta, Egypt, causing a fire that spread to another ship.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
